Media Release

23 September 2015

Further data on selexipag (Uptravi) and macitentan (Opsumit) to be presented at European Respiratory Society (ERS) Congress 2015

ALLSCHWIL, SWITZERLAND – 23 September 2015 – Actelion Ltd (SIX: ATLN) today announced that key data from the pivotal Phase III GRIPHON study with the investigational drug selexipag (Uptravi®) will be shared through an oral presentation at the European Respiratory Society (ERS) Congress in Amsterdam, Netherlands.

The oral presentation, titled ‘Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results’ will be given by Professor Olivier Sitbon from the Hospital Le Kremlin Bicêtre, Paris, France, at 11.15 on 30 September. The abstract can be found in the congress program online.

The ERS Congress will also see the presentation of further information on macitentan (Opsumit®), with a poster titled ‘Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives’. The poster will be presented in a poster discussion session by Dr Noémie Hurst from 10.45 on 28 September. The abstract can be found in the congress program online.

###

Notes to Editor:

SELEXIPAG AT ERS-15

Oral presentation:

Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results


Wednesday, September 30, 11:15 – 11:30, Room 4.1

MACITENTAN AT ERS-15

Poster presentation:

Pharmacokinetics and safety of concomitant macitentan and hormonal contraceptives

N. Hurst, M. Pellek, P.N. Sidharta, J. Dingemanse

Monday, September 28, 10:45 - 12:45, Room E102
ACTELION LTD

Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization of innovative drugs for diseases with significant unmet medical needs.

Actelion is a leader in the field of pulmonary arterial hypertension (PAH). Our portfolio of PAH treatments covers the spectrum of disease, from WHO Functional Class (FC) II through to FC IV, with oral, inhaled and intravenous medications. Although not available in all countries, Actelion has treatments approved by health authorities for a number of specialist diseases including Type 1 Gaucher disease, Niemann-Pick type C disease, Digital Ulcers in patients suffering from systemic sclerosis, and mycosis fungoides type cutaneous T-cell lymphoma.

Founded in late 1997, with now over 2,400 dedicated professionals covering all key markets around the world including Europe, the US, Japan, China, Russia and Mexico, Actelion has its corporate headquarters in Allschwil / Basel, Switzerland.

Actelion shares are traded on the SIX Swiss Exchange (ticker symbol: ATLN) as part of the Swiss blue-chip index SMI (Swiss Market Index SMI®). All trademarks are legally protected.

For further information please contact:

Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Actelion Pharmaceuticals Ltd, Gewerbestrasse 16, CH-4123 Allschwil
+41 61 565 62 62
http://www.actelion.com

The above information contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "are expected to", "will", "will continue", "should", "would be", "seeks", "pending" or "anticipates" or similar expressions, or by discussions of strategy, plans or intentions. Such statements include descriptions of the company's investment and research and development programs and anticipated expenditures in connection therewith, descriptions of new products expected to be introduced by the company and anticipated customer demand for such products and products in the company's existing portfolio. Such statements reflect the current views of the company with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the actual results, performance or achievements of the company to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.